Orlando Slim Shot/Wegovy
Semiglutide (Wegovy) is a glucagon-like peptide-1 (GLP-1) analogue that is approved, at doses up to 1 mg administered subcutaneously once weekly, for the treatment of type 2 diabetes in adults and for reducing the risk of cardiovascular events in persons with type 2 diabetes and cardiovascular disease.1
In June 2021, The U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.
Semiglutide is administered weekly with a subcutaneous injection. We also recommend treatment with a supplemental metabolism enhancing medication to be used concurrently with Semiglutide.
At NV Medical Orlando, we provide comprehensive evaluation and treatment for weight loss with Semiglutide. Our treatment program includes a weekly in person or virtual program. We have several treatment packages available. Please call the office at (407) 730-4244 for further information.
References
1. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, revised. 2020 (https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/209637s003lbl.pdf.